Chemotherapy in Advanced Non-Small Cell Lung Cancer

ABSTRACT

Although patients with advanced non-small cell lung cancer (NSCLC) cannot be cured, cytotoxic chemotherapy in patients with reasonable performance status can improve overall survival and quality of life. No one regimen has demonstrated superior efficacy results, and platinum-based doublets remain the current standard of care. The toxicity profiles of acceptable regimens differ, allowing treatment to be tailored to a specific patient. The duration of first-line chemotherapy should not exceed four to six cycles. Second- and third-line treatment regimens also have established survival benefits, which has led to increasing improvements in overall survival for patients with advanced NSCLC. Treatment approaches in patients with borderline performance status remain controversial. Although the optimal treatment approach for elderly patients has not yet been established, it is clear that the elderly do benefit from chemotherapy, and fit elderly patients can be treated with the same regimens as younger patients. It is critical that all patients with advanced NSCLC be referred to medical oncologists. Patients considering chemotherapy must have a clear understanding of the expected benefits, limitations, and toxicities.

Chemotherapy - advanced non-small cell lung cancer

REFERENCES

1 Excluding the rare patient with oligometastatic disease, or a solitary metastasis in the brain or adrenal gland, who can be approached with curative intent.

2 PS 3 patients were included in the randomized study that established the survival advantage or erlotinib over best supportive care.

• 1 Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group.  BMJ. 1995;  311 899-909
• 2 Cullen M H, Billingham L J, Woodroffe C M et al.. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.  J Clin Oncol. 1999;  17 3188-3194
• 3 Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.  J Natl Cancer Inst. 1999;  91 66-72
• 4 Anderson H, Hopwood P, Stephens R J et al.. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.  Br J Cancer. 2000;  83 447-453
• 5 Wozniak A J, Crowley J J, Balcerzak S P et al.. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.  J Clin Oncol. 1998;  16 2459-2465
• 6 Finkelstein D M, Ettinger D S, Ruckdeschel J C. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.  J Clin Oncol. 1986;  4 702-709
• 7 Bonomi P, Kim K, Fairclough D et al.. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.  J Clin Oncol. 2000;  18 623-631
• 8 Kelly K, Crowley J, Bunn Jr P A et al.. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial.  J Clin Oncol. 2001;  19 3210-3218
• 9 Schiller J, Harrington D, Sandler A et al.. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) [abstract 2]. In: 36th Annual Meeting of the American Society of Clinical Oncology; 2000; New Orleans, LA 2000
• 10 Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.  BMJ. 1991;  303 884-893
• 11 du Bois A, Luck H J, Meier W et al.. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.  J Natl Cancer Inst. 2003;  95 1320-1329
• 12 Horwich A, Sleijfer D T, Fossa S D et al.. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.  J Clin Oncol. 1997;  15 1844-1852
• 13 Bajorin D F, Sarosdy M F, Pfister D G et al.. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.  J Clin Oncol. 1993;  11 598-606
• 14 Rosell R, Gatzemeier U, Betticher D C et al.. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.  Ann Oncol. 2002;  13 1539-1549
• 15 Klastersky J, Sculier J P, Lacroix H et al.. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.  J Clin Oncol. 1990;  8 1556-1562
• 16 Paccagnella A, Favaretto A, Oniga F et al.. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer: a multicenter, randomized phase III trial.  Lung Cancer. 2004;  43 83-91
• 17 Zatloukal P, Petruzelka L, Zemanova M et al.. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.  Lung Cancer. 2003;  41 321-331
• 18 Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer.  J Clin Oncol. 2004;  22 3852-3859
• 19 Gridelli C, Gallo C, Shepherd F A et al.. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.  J Clin Oncol. 2003;  21 3025-3034
• 20 Georgoulias V, Papadakis E, Alexopoulos A et al.. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.  Lancet. 2001;  357 1478-1484
• 21 Kosmidis P, Mylonakis N, Nicolaides C et al.. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.  J Clin Oncol. 2002;  20 3578-3585
• 22 Smit E F, van Meerbeeck J P, Lianes P et al.. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975.  J Clin Oncol. 2003;  21 3909-3917
• 23 Stathopoulos G P, Veslemes M, Georgatou N et al.. Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial.  Ann Oncol. 2004;  15 1048-1055
• 24 Abratt R P, Szczesna A, Mattson K et al.. Vinorelbine (NVB)-carboplatin vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patient benefit analysis [abstract 7016].  J Clin Oncol. 2004;  22(Suppl 14)
• 25 Lilenbaum R C, Langenberg P, Dickersin K. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung carcinoma: a meta-analysis of response, toxicity, and survival.  Cancer. 1998;  82 116-126
• 26 Lilenbaum R C, Herndon II J E, List M A et al.. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).  J Clin Oncol. 2005;  23 190-196
• 27 Delbaldo C, Michiels S, Syz N, Soria J C, Le Chevalier T, Pignon J P. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis.  JAMA. 2004;  292 470-484
• 28 Giaccone G, Herbst R S, Manegold C et al.. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1.  J Clin Oncol. 2004;  22 777-784
• 29 Herbst R S, Giaccone G, Schiller J H et al.. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2.  J Clin Oncol. 2004;  22 785-794
• 30 Gatzmeier U, Pluzanska A, Szczesna A et al.. Results of a phase III trial of erlotinib combined with cisplatin and gemcitabine in advanced non-small cell lung cancer [abstract 7010]. 2004 Annual Meeting Proceedings.  J Clin Oncol. 2004;  22(Suppl 14)
• 31 Herbst R S, Prager D, Hermann R et al.. TRIBUTE-A phase III trial of erlotinib combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer [abstract 7011]. 2004 Annual Meeting Proceedings.  J Clin Oncol. 2004;  22(Suppl 14)
• 32 Lynch T J, Raju R, Lind M et al.. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report [abstract 2504].  Proc Am Soc Clin Oncol. 2003;  22 623
• 33 Bissett D, O’Byrne K J, von Pawel J et al.. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer.  J Clin Oncol. 2005;  23 842-849
• 34 Hurwitz H, Fehrenbacher L, Cartwright T et al.. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC [abstract 3646].  Proc Am Soc Clin Oncol. 2003; 
• 35 Johnson D H, Fehrenbacher L, Novotny W F et al.. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.  J Clin Oncol. 2004;  22 2184-2191
• 36 Dubey S, Brown R L, Esmond S L, Bowers B J, Healy J M, Schiller J H. Patient preferences in choosing chemotherapy regimnes for advanced non-small cell lung cancer.  The Journal of Supportive Oncology. 2005;  3 149-154
• 37 Smith I E, O’Brien M E, Talbot D C et al.. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.  J Clin Oncol. 2001;  19 1336-1343
• 38 Socinski M, Kies M, Schell M et al.. Duration of therapy in stage IIIB/IV non-small cell lung Cancer (NSCLC): a multi-institutional phase III trial [abstract 1232]. In: 37th Annual Meeting of the American Society of Clinical Oncology; 2001; San Francisco, CA 2001
• 39 Pfister D G, Johnson D H, Azzoli C G et al.. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.  J Clin Oncol. 2004;  22 330-353
• 40 Shepherd F A, Dancey J, Ramlau R et al.. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.  J Clin Oncol. 2000;  18 2095-2103
• 41 Fossella F V, DeVore R, Kerr R N et al.. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.  J Clin Oncol. 2000;  18 2354-2362
• 42 Hanna N, Shepherd F A, Fossella F V et al.. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.  J Clin Oncol. 2004;  22 1589-1597
• 43 Shepherd F A, Pereira J R, Ciuleanu T E et al.. A randomized placebo-controlled trial in patients with advanced non-small cell lung cancer following failure of first- or second-line chemotherapy [abstract 7022]. 2004 ASCO Annual Meeting Proceedings.  J Clin Oncol. 2004;  22(Suppl 14)
• 44 Sweeney C J, Zhu J, Sandler A B et al.. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma.  Cancer. 2001;  92 2639-2647
• 45 Tester W J, Stephenson P, Langer C J, Schiller J H, Johnson D H, Rapoport B L. ECOG 1599: randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC) [abstract 7055].  J Clin Oncol. 2004;  22(Suppl 14)
• 46 Earle C C, Tsai J S, Gelber R D, Weinstein M C, Neumann P J, Weeks J C. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis.  J Clin Oncol. 2001;  19 1064-1070
• 47 Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.  J Natl Cancer Inst. 1999;  91 66-72
• 48 Gridelli C, Perrone F, Gallo C et al.. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.  J Natl Cancer Inst. 2003;  95 362-372
• 49 Frasci G, Lorusso V, Panza N et al.. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer: a Southern Italy Cooperative Oncology Group (SICOG) phase III trial.  Lung Cancer. 2001;  34(Suppl 4) S65-S69
• 50 Le Chevalier T, Brisgand D, Douillard J Y et al.. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.  J Clin Oncol. 1994;  12 360-367
• 51 Langer C J, Manola J, Bernardo P et al.. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.  J Natl Cancer Inst. 2002;  94 173-181
• 52 Earle C C, Venditti L N, Neumann P J et al.. Who gets chemotherapy for metastatic lung cancer?.  Chest. 2000;  117 1239-1246
• 53 Earle C C, Neumann P J, Gelber R D, Weinstein M C, Weeks J C. Impact of referral patterns on the use of chemotherapy for lung cancer.  J Clin Oncol. 2002;  20 1786-1792
• 54 Silvestri G, Pritchard R, Welch H G. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews.  BMJ. 1998;  317 771-775
• 55 Brundage M D, Feldman-Stewart D, Cosby R et al.. Cancer patients' attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision support.  Patient Educ Couns. 2001;  45 149-157